A 28-year-old woman from Mumbai with a history of MDR-TB (treated with levofloxacin, amikacin, and ethionamide for 6 months) presents with persistent productive cough and fever. Repeat sputum smear microscopy remains positive. Drug susceptibility testing reveals resistance to isoniazid, rifampicin, fluoroquinolones, and injectable agents (amikacin). She is now classified as having XDR-TB. What is the preferred drug of choice to add to her regimen?

Explanation

## XDR-TB Management and Bedaquiline **Key Point:** XDR-TB (extensively drug-resistant TB) is defined as MDR-TB with additional resistance to any fluoroquinolone AND at least one injectable second-line agent. Bedaquiline, a novel ATP synthase inhibitor, is now a core component of WHO-recommended XDR-TB regimens. ### Definition and Epidemiology of XDR-TB | Feature | Details | |---------|----------| | Definition | Resistance to isoniazid + rifampicin + any fluoroquinolone + any injectable (amikacin, kanamycin, or capreomycin) | | Global burden | ~10% of MDR-TB cases are XDR-TB | | India prevalence | ~2–3% of TB cases; higher in urban centers | | Mortality | 30–50% if untreated; 20–30% with newer regimens | | Treatment duration | 20 months or longer | ### WHO-Recommended XDR-TB Regimen (2023) The preferred regimen includes: 1. **Bedaquiline** (6 months intensive, then continue) — ATP synthase inhibitor; bactericidal; excellent lung penetration 2. **Linezolid** (20 months) — Protein synthesis inhibitor; excellent intracellular and CNS penetration 3. **Levofloxacin** (if susceptible) or **moxifloxacin** — Though fluoroquinolone-resistant in this case, alternatives include: - **Clofazimine** (20 months) — Redox-active agent; slow-acting but synergistic 4. **Pyrazinamide** ± **ethambutol** — Adjunctive agents **High-Yield:** Bedaquiline is the **first-line novel agent** for XDR-TB. It is bactericidal, has a long half-life (5–7 days), and achieves high lung concentrations. Studies show it improves cure rates in XDR-TB from ~20% (without bedaquiline) to ~50–60% (with bedaquiline). ### Mechanism of Action of Bedaquiline ```mermaid flowchart TD A[Bedaquiline enters mycobacterial cell]:::action --> B[Binds to ATP synthase subunit C]:::action B --> C[Inhibits ATP synthesis]:::action C --> D[Depletion of cellular energy]:::outcome D --> E[Rapid bactericidal activity]:::outcome E --> F[Effective in XDR-TB]:::action ``` **Clinical Pearl:** Bedaquiline has a **long half-life** (~5–7 days), allowing for once-daily dosing and good intracellular penetration. It is particularly valuable in XDR-TB where fluoroquinolone and injectable resistance limit options. ### Typical XDR-TB Regimen Structure **Intensive Phase (6 months):** - Bedaquiline + Linezolid + Clofazimine + Pyrazinamide **Continuation Phase (14 months):** - Bedaquiline + Linezolid + Clofazimine ± Pyrazinamide **Warning:** Bedaquiline has potential for **QT prolongation** (monitor ECG at baseline and weeks 2, 8, 12, 24). Avoid concurrent QT-prolonging drugs (fluoroquinolones, clofazimine). Hepatotoxicity is rare but monitor LFTs. **Mnemonic:** **BLiC** = **B**edaquiline + **Li**nezolid + **C**lofazimine (the "new trio" for XDR-TB). [cite:WHO TB Report 2023; NTEP TB India Guidelines 2023; Harrison 21e Ch 158]